173 related articles for article (PubMed ID: 21035172)
1. The expression of the miRNA-200 family in endometrial endometrioid carcinoma.
Lee JW; Park YA; Choi JJ; Lee YY; Kim CJ; Choi C; Kim TJ; Lee NW; Kim BG; Bae DS
Gynecol Oncol; 2011 Jan; 120(1):56-62. PubMed ID: 21035172
[TBL] [Abstract][Full Text] [Related]
2. Expression profile of mammalian microRNAs in endometrioid adenocarcinoma.
Wu W; Lin Z; Zhuang Z; Liang X
Eur J Cancer Prev; 2009 Feb; 18(1):50-5. PubMed ID: 19077565
[TBL] [Abstract][Full Text] [Related]
3. [Expression of microRNAs in endometrioid adenocarcinoma].
Liu X; Xia W; Dai YM; Shao NS; Zhang WY
Zhonghua Yi Xue Za Zhi; 2009 May; 89(19):1365-7. PubMed ID: 19615196
[TBL] [Abstract][Full Text] [Related]
4. Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis.
Romero-Pérez L; Castilla MÁ; López-García MÁ; Díaz-Martín J; Biscuola M; Ramiro-Fuentes S; Oliva E; Matias-Guiu X; Prat J; Cano A; Moreno-Bueno G; Palacios J
Hum Pathol; 2013 Feb; 44(2):244-54. PubMed ID: 22974476
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of endometrial carcinoma cell growth using antisense estrogen receptor oligodeoxyribonucleotides.
Taylor AH; al-Azzawi F; Pringle JH; Bell SC
Anticancer Res; 2002; 22(6C):3993-4003. PubMed ID: 12553024
[TBL] [Abstract][Full Text] [Related]
7. [Study of differential gene expression in different stage human endometrial cancer].
Wan XP; Cai B; Liu L; Xi XW; Yang YX
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):38-42. PubMed ID: 16635327
[TBL] [Abstract][Full Text] [Related]
8. Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary.
Guirguis A; Elishaev E; Oh SH; Tseng GC; Zorn K; DeLoia JA
Gynecol Oncol; 2008 Feb; 108(2):370-6. PubMed ID: 18083218
[TBL] [Abstract][Full Text] [Related]
9. The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma.
Park YA; Lee JW; Choi JJ; Jeon HK; Cho Y; Choi C; Kim TJ; Lee NW; Kim BG; Bae DS
Gynecol Oncol; 2012 Jan; 124(1):125-33. PubMed ID: 22015043
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer.
Nakamura M; Kyo S; Zhang B; Zhang X; Mizumoto Y; Takakura M; Maida Y; Mori N; Hashimoto M; Ohno S; Inoue M
Hum Pathol; 2010 Nov; 41(11):1516-29. PubMed ID: 20800872
[TBL] [Abstract][Full Text] [Related]
11. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
12. [Telomerase antisense inhibition and chemotherapeutic combination treatments for the proliferation of endometrial cancer in vitro and in vivo].
Chen XJ; Zheng W; Chen LL; Chen ZB; Wang SQ
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1721-5. PubMed ID: 15569435
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling.
Risinger JI; Maxwell GL; Chandramouli GV; Aprelikova O; Litzi T; Umar A; Berchuck A; Barrett JC
Cancer Res; 2005 Jun; 65(12):5031-7. PubMed ID: 15958545
[TBL] [Abstract][Full Text] [Related]
14. cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer.
Chen Y; Yao Y; Zhang L; Li X; Wang Y; Zhao L; Wang J; Wang G; Shen D; Wei L; Zhao J
Exp Mol Pathol; 2011 Aug; 91(1):373-84. PubMed ID: 21540026
[TBL] [Abstract][Full Text] [Related]
15. LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma.
Marshall AD; van Geldermalsen M; Otte NJ; Anderson LA; Lum T; Vellozzi MA; Zhang BK; Thoeng A; Wang Q; Rasko JE; Holst J
Int J Cancer; 2016 Dec; 139(11):2529-39. PubMed ID: 27486861
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.
Choi CH; Park YA; Choi JJ; Song T; Song SY; Lee YY; Lee JW; Kim TJ; Kim BG; Bae DS
Gynecol Oncol; 2012 Jul; 126(1):124-31. PubMed ID: 22525818
[TBL] [Abstract][Full Text] [Related]
17. Expression of the epidermal growth factor system in endometrioid endometrial cancer.
Ejskjaer K; Sørensen BS; Poulsen SS; Forman A; Nexø E; Mogensen O
Gynecol Oncol; 2007 Jan; 104(1):158-67. PubMed ID: 16962163
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of DNA methyltransferase 3B expression in endometrial cancers.
Jin F; Dowdy SC; Xiong Y; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Feb; 96(2):531-8. PubMed ID: 15661247
[TBL] [Abstract][Full Text] [Related]
19. Placental leucine aminopeptidase (P-LAP) expression is associated with chemosensitivity in human endometrial carcinoma.
Shibata K; Kikkawa F; Kondo C; Mizokami Y; Kajiyama H; Ino K; Nomura S; Mizutani S
Gynecol Oncol; 2004 Nov; 95(2):307-13. PubMed ID: 15491750
[TBL] [Abstract][Full Text] [Related]
20. microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs.
Devor EJ; Hovey AM; Goodheart MJ; Ramachandran S; Leslie KK
Oncol Rep; 2011 Oct; 26(4):995-1002. PubMed ID: 21725615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
